|Bid||17.190 x 3100|
|Ask||17.200 x 7700|
|Day's Range||17.165 - 17.420|
|52 Week Range||15.220 - 50.570|
|PE Ratio (TTM)||-2.81|
|Dividend & Yield||1.10 (6.43%)|
|1y Target Est||N/A|
This highly levered, acquisition-focused growth story has come crashing down recently. It is eerily similar to when the highly-levered, acquisition-focused growth story of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) fell apart not too long ago. As we all know, VRX stock went bust and hasn’t recovered.
Biopharma companies are using court battles and reformulations to prevent generic-drug makers from capturing sales.
Long-term investors take note, because bargains abound.